FREE SHIPPING over $40
OVER 9000 FIVE-STAR REVIEWS
5% OFF ALL SUBSCRIPTIONS
100% HAPPINESS GUARANTEE
Analyze Diet
0
Home / Equine Research Bank / PLoS One / Acylcarnitines profile best predicts survival in horses with...
PloS one2017; 12(8); e0182761; doi: 10.1371/journal.pone.0182761

Acylcarnitines profile best predicts survival in horses with atypical myopathy.

Abstract: Equine atypical myopathy (AM) is caused by hypoglycin A intoxication and is characterized by a high fatality rate. Predictive estimation of survival in AM horses is necessary to prevent unnecessary suffering of animals that are unlikely to survive and to focus supportive therapy on horses with a possible favourable prognosis of survival. We hypothesized that outcome may be predicted early in the course of disease based on the assumption that the acylcarnitine profile reflects the derangement of muscle energetics. We developed a statistical model to prognosticate the risk of death of diseased animals and found that estimation of outcome may be drawn from three acylcarnitines (C2, C10:2 and C18 -carnitines) with a high sensitivity and specificity. The calculation of the prognosis of survival makes it possible to distinguish the horses that will survive from those that will die despite severe signs of acute rhabdomyolysis in both groups.
Get Full Text
Publication Date: 2017-08-28 PubMed ID: 28846683PubMed Central: PMC5573150DOI: 10.1371/journal.pone.0182761Google Scholar: Lookup
The Equine Research Bank provides access to a large database of publicly available scientific literature. Inclusion in the Research Bank does not imply endorsement of study methods or findings by Mad Barn.
LinkedInCopy
  • Journal Article

Summary

This research summary has been generated with artificial intelligence and may contain errors and omissions. Refer to the original study to confirm details provided. Submit correction.

The research article examines equine atypical myopathy (AM), a disease caused by hypoglycin A intoxication in horses, and how survival outcomes can be predicted based on the acylcarnitine profile, a marker of muscle energetics. The researchers developed a statistical model which showed that the outcome could be predicted with high sensitivity and specificity using three specific acylcarnitines.

Introduction to Atypical Myopathy

  • Atypical Myopathy (AM) is a fatal disease prevalent in horses, induced by hypoglycin A intoxication.
  • The illness is characterized by a high mortality rate, and thus, a mechanism to predict survival outcomes can help adjust supportive therapy while minimizing the suffering of animals predicted with a low chance of survival.

Study Hypothesis and Approach

  • The researchers hypothesized that survival outcomes in AM infected horses could be predicted by examining the acylcarnitine profile, which provides information about muscle energetics and their derangement in disease conditions.
  • To test this hypothesis, they developed a statistical model aimed at assessing the death risk in AM horses.

Findings and Interpretations

  • The research found that three specific acylcarnitines – C2, C10:2 and C18 – enabled accurate estimations of survival outcomes with high sensitivity and specificity.
  • This finding suggests that despite severe symptoms of acute rhabdomyolysis (rapid muscle breakdown) present in AM affected horses, the prognosis of survival can be calculated accurately by examining these specific acylcarnitines.
  • That means, the model can distinguish between horses likely to survive and those likely to succumb to the disease, allowing caregivers to make informed decisions about focussing supportive therapies and managing crisis responses.

Implications of the Study

  • The research provides a promising breakthrough in managing Atypical Myopathy in horses by predicting survival outcomes at an early disease stage.
  • This would help veterinarians to provide suitable treatments and prevent unnecessary suffering of horses.
  • Moreover, it may contribute to the broader understanding of muscle energetics in disease conditions and how they might be used to predict disease outcomes in future studies.

Cite This Article

APA
Boemer F, Detilleux J, Cello C, Amory H, Marcillaud-Pitel C, Richard E, van Galen G, van Loon G, Lefère L, Votion DM. (2017). Acylcarnitines profile best predicts survival in horses with atypical myopathy. PLoS One, 12(8), e0182761. https://doi.org/10.1371/journal.pone.0182761

Publication

PloS one
ISSN: 1932-6203
NlmUniqueID: 101285081
Country: United States
Language: English
Volume: 12
Issue: 8
Pages: e0182761

Researcher Affiliations

Boemer, François
  • Biochemical Genetics Laboratory, CHU Sart Tilman, University of Liege, Liege, Belgium.
Detilleux, Johann
  • Department of animal Productions: Biostatistics, Economy and animal selection, Fundamental and Applied Research for Animals & Health (FARAH), Faculty of Veterinary Medicine, University of Liege, Liege, Belgium.
Cello, Christophe
  • Biochemical Genetics Laboratory, CHU Sart Tilman, University of Liege, Liege, Belgium.
Amory, Hélène
  • Equine Pole, Fundamental and Applied Research for Animals & Health (FARAH), Faculty of Veterinary Medicine, University of Liege, Liege, Belgium.
Marcillaud-Pitel, Christel
  • Réseau d'EpidémioSurveillance en Pathologie Equine (RESPE), Caen, France.
Richard, Eric
  • Normandie Université, UNICAEN, Labéo Frank Duncombe, Caen, France.
van Galen, Gaby
  • Equine Pole, Fundamental and Applied Research for Animals & Health (FARAH), Faculty of Veterinary Medicine, University of Liege, Liege, Belgium.
van Loon, Gunther
  • Large Animal Internal Medicine, Gent University, Gent, Belgium.
Lefère, Laurence
  • Large Animal Internal Medicine, Gent University, Gent, Belgium.
Votion, Dominique-Marie
  • Equine Pole, Fundamental and Applied Research for Animals & Health (FARAH), Faculty of Veterinary Medicine, University of Liege, Liege, Belgium.

MeSH Terms

  • Animals
  • Carnitine / analogs & derivatives
  • Carnitine / blood
  • Horse Diseases / blood
  • Horse Diseases / mortality
  • Horses
  • Muscular Diseases / blood
  • Muscular Diseases / mortality
  • Muscular Diseases / veterinary
  • Prognosis
  • Survival Rate

Conflict of Interest Statement

Competing Interests: The authors have declared that no competing interests exist.

References

This article includes 35 references
  1. Baise E, Habyarimana JA, Amory H, Boemer F, Douny C, Gustin P. Samaras and seedlings of Acer pseudoplatanus are potential sources of hypoglycin A intoxication in atypical myopathy without necessarily inducing clinical signs.. Equine veterinary Journal 2015.
    doi: 10.1111/evj.12499pubmed: 26278545google scholar: lookup
  2. Votion DM, van Galen G, Sweetman L, Boemer F, de Tullio P, Dopagne C. Identification of methylenecyclopropyl acetic acid in serum of European horses with atypical myopathy.. Equine Vet J 2014;46(2):146–9.
    doi: 10.1111/evj.12117pubmed: 23773055google scholar: lookup
  3. Westermann CM, van Leeuwen R, van Raamsdonk LW, Mol HG. Hypoglycin A Concentrations in Maple Tree Species in the Netherlands and the Occurrence of Atypical Myopathy in Horses.. J Vet Intern Med 2016;30(3):880–4.
    doi: 10.1111/jvim.13927pmc: PMC4913566pubmed: 26995161google scholar: lookup
  4. Westermann CM, Dorland L, Votion DM, de Sain-van der Velden MG, Wijnberg ID, Wanders RJ. Acquired multiple Acyl-CoA dehydrogenase deficiency in 10 horses with atypical myopathy.. Neuromuscul Disord 2008;18(5):355–64.
    doi: 10.1016/j.nmd.2008.02.007pubmed: 18406615google scholar: lookup
  5. Bochnia M, Ziegler J, Sander J, Uhlig A, Schaefer S, Vollstedt S. Hypoglycin A content in blood and urine discriminates horses with atypical myopathy from clinically normal horses grazing on the same pasture.. PLoS One 2015.
    doi: 10.1371/journal.pone.0136785pmc: PMC4574941pubmed: 26378918google scholar: lookup
  6. Sander J, Cavalleri JM, Terhardt M, Bochnia M, Zeyner A, Zuraw A. Rapid diagnosis of hypoglycin A intoxication in atypical myopathy of horses.. J Vet Diagn Invest 2016;28(2):98–104.
    doi: 10.1177/1040638715624736pubmed: 26965229google scholar: lookup
  7. Boemer F, Deberg M, Schoos R, Baise E, Amory H, Gault G. Quantification of hypoglycin A in plasma using aTRAQ(R) kit.. Journal of Chromatography B 2015;997:75–80.
    pubmed: 26094208
  8. van Galen G, Marcillaud Pitel C, Saegerman C, Patarin F, Amory H, Baily JD. European outbreaks of atypical myopathy in grazing equids (2006–2009): Spatiotemporal distribution, history and clinical features.. Equine Vet J 2012;44(5):614–20.
    doi: 10.1111/j.2042-3306.2012.00556.xpubmed: 22448904google scholar: lookup
  9. van Galen G, Votion DM. Management of cases suffering from atypical myopathy: Interpretations of descriptive, epidemiological and pathophysiological findings. Part 1: First aid, cardiovascular, nutritional and digestive care.. Equine Veterinary Education 2013;25(5):264–70.
  10. van Galen G, Votion DM. Management of cases suffering from atypical myopathy: Interpretations of descriptive, epidemiological and pathophysiological findings. Part 2: Muscular, urinary, respiratory and hepatic care, and inflammatory/infectious status.. Equine Veterinary Education 2013;25(6):264–70.
  11. van Galen G, Saegerman C, Marcillaud Pitel C, Patarin F, Amory H, Baily JD. European outbreaks of atypical myopathy in grazing horses (2006–2009): Determination of indicators for risk and prognostic factors.. Equine Vet J 2012;44(5):621–5.
    doi: 10.1111/j.2042-3306.2012.00555.xpubmed: 22413891google scholar: lookup
  12. Gonzalez-Medina S, Ireland JL, Piercy RJ, Newton JR, Votion DM. Equine Atypical Myopathy in the UK: Epidemiological characteristics of cases reported from 2011 to 2015 and factors associated with survival.. Equine Vet J 2017.
    doi: 10.1111/evj.12694pubmed: 28445006google scholar: lookup
  13. Carlier J, Guitton J, Moreau C, Boyer B, Bévalot F, Fanton L. A validated method for quantifying hypoglycin A in whole blood by UHPLC-HRMS/MS.. J Chromatogr B Analyt Technol Biomed Life Sci 2015;978–979:70–7.
    doi: 10.1016/j.jchromb.2014.11.029pubmed: 25531872google scholar: lookup
  14. Boemer F, Deberg M, Schoos R, Baise E, Amory H, Gault G. Quantification of hypoglycin A in serum using aTRAQ(R) assay.. J Chromatogr B Analyt Technol Biomed Life Sci 2015;997:75–80.
    doi: 10.1016/j.jchromb.2015.06.004pubmed: 26094208google scholar: lookup
  15. Chace DH, Pons R, Chiriboga CA, McMahon DJ, Tein I, Naylor EW. Neonatal blood carnitine concentrations: normative data by electrospray tandem mass spectometry.. Pediatr Res 2003;53(5):823–9.
    doi: 10.1203/01.PDR.0000059220.39578.3Dpubmed: 12612202google scholar: lookup
  16. Filee R, Schoos R, Boemer F. Evaluation of physiological amino acids profiling by tandem mass spectrometry.. J Inherit Metab Dis 2014;13:119–28.
    pmc: PMC4110342pubmed: 24190798
  17. Detilleux J, Arendt J, Lomba F, Leroy P. Methods for estimating areas under receiver-operating characteristic curves: illustration with somatic-cell scores in subclinical intramammary infections.. Prev Vet Med 1999;41(2–3):75–88.
    pubmed: 10448938
  18. Esbjørn Høffer S, Votion DM, Andeberg M, Boemer F, Nautrup Olsen S, Van Galen G. Atypical Myopathy in Denmark Confirmed With the aTRAQ Assay.. Journal of Equine Veterinary Science 2016;(47):77–9.
  19. McKenzie RK, Hill FI, Habyarimana JA, Boemer F, Votion DM. Detection of hypoglycin A in the seeds of sycamore (Acer pseudoplatanus) and box elder (A. negundo) in New Zealand; the toxin associated with cases of equine atypical myopathy.. N Z Vet J 2016;64(3):182–7.
    doi: 10.1080/00480169.2015.1123123pubmed: 26593855google scholar: lookup
  20. Votion DM, Linden A, Delguste C, Amory H, Thiry E, Engels P. Atypical myopathy in grazing horses: a first exploratory data analysis.. The Veterinary Journal 2009;180(1):77–87.
    doi: 10.1016/j.tvjl.2008.01.016pubmed: 18396430google scholar: lookup
  21. Votion DM, Linden A, Saegerman C, Engels P, Erpicum M, Thiry E. History and clinical features of atypical myopathy in horses in Belgium (2000–2005).. Journal of Veterinary Internal Medicine 2007;21(6):1380–91.
    pubmed: 18196750
  22. van Galen G, Cerri S, Porter S, Saegerman C, Lefere L, Roscher K. Traditional and quantitative assessment of Acid-base and shock variables in horses with atypical myopathy.. J Vet Intern Med 2013;27(1):186–93.
    doi: 10.1111/jvim.12003pubmed: 23193982google scholar: lookup
  23. Verheyen T, Decloedt A, De Clercq D, van Loon G. Cardiac changes in horses with atypical myopathy.. J Vet Intern Med 2012;26(4):1019–26.
    doi: 10.1111/j.1939-1676.2012.00945.xpubmed: 22646196google scholar: lookup
  24. Von Holt C. Methylenecyclopropaneacetic acid, a metabolite of hypoglycin.. Biochim Biophys Acta 1966;125(1):1–10.
    pubmed: 5968592
  25. Tanaka K, Kean EA, Johnson B. Jamaican vomiting sickness. Biochemical investigation of two cases.. N Engl J Med 1976;295(9):461–7.
    doi: 10.1056/NEJM197608262950901pubmed: 940578google scholar: lookup
  26. Barceloux DG. Akee fruit and Jamaican vomiting sickness (Blighia sapida Koenig).. Dis Mon 2009;55(6):318–26.
    doi: 10.1016/j.disamonth.2009.03.002pubmed: 19446675google scholar: lookup
  27. Shih VE, Tanaka K. Plasma and urine amino acid changes in rats treated with hypoglycin.. Clin Chim Acta 1978;88(3):539–43.
    pubmed: 699343
  28. Delguste C, Cassart D, Baise E, Linden A, Schwarzwald C, Feige K. Myopathies atypiques chez les chevaux au pré: une série de cas en Belgique.. Ann Med Vet 2002;146:231–43.
  29. Grunes DE, Scordi-Bello I, Suh M, Florman S, Yao J, Fiel MI. Fulminant hepatic failure attributed to Ackee fruit ingestion in a patient with sickle cell trait.. Case Reports in Transplantation 2012;(Article ID 739238):4 pages.
    doi: 10.1155/2012/739238pmc: PMC3504255pubmed: 23259140google scholar: lookup
  30. Osmundsen H, Sherratt HS. A novel mechanism for inhibition of beta-oxidation by methylenecyclopropylacetyl-CoA, a metabolite of hypoglycin.. FEBS Lett 1975;55(1):38–41.
    pubmed: 1140426
  31. Tanaka K, Miller EM, Isselbacher KJ. Hypoglycin A: a specific inhibitor of isovaleryl CoA dehydrogenase.. Proc Natl Acad Sci U S A 1971;68(1):20–4.
    pmc: PMC391092pubmed: 5276292
  32. Tanaka K. On the mode of action of hypoglycin A. 3. Isolation and identification of cis-4-decene-1,10-dioic, cis, cis-4,7-decadiene-1,10-dioic, cis-4-octene-1,8-dioic, glutaric, and adipic acids, N-(methylenecyclopropyl)acetylglycine, and N-isovalerylglycine from urine of hypoglycin A-treated rats.. J Biol Chem 1972;247(23):7465–78.
    pubmed: 4636318
  33. Ikeda Y, Tanaka K. Selective inactivation of various acyl-CoA dehydrogenases by (methylenecyclopropyl)acetyl-CoA.. Biochim Biophys Acta 1990;1038(2):216–21.
    pubmed: 2331485
  34. Lai MT, Li D, Oh E, Liu HW. Inactivation of medium-chain acyl-CoA dehydrogenase by a metabolite of hypoglycin: characterization of the major turnover product and evidence suggesting an alternative flavin modification pathway.. J Am Chem Soc 1993;115(5):1619–28.
  35. Entman M, Bressler R. The mechanism of action of hypoglycin on long-chain fatty acid oxidation.. Mol Pharmacol 1967;3(4):333–40.
    pubmed: 6033633
Subscribe to our newsletter
Join 99,357 horse owners like you who receive our email updates on horse health and nutrition.